Thrombosis
Conference Coverage
Perioperative rVWF alone sufficient for some VWD patients
GLASGOW—Recombinant von Willebrand factor (rVWF) alone can be sufficient as perioperative management for some patients with severe von Willebrand...
News
FDA clears device for treatment of PE
The US Food and Drug Administration (FDA) has granted 510(k) clearance to the FlowTriever System for the treatment of pulmonary embolism (PE)....
Conference Coverage
Emicizumab controls bleeding regardless of inhibitors
GLASGOW—Emicizumab prophylaxis provides “clinically meaningful” control of bleeding whether or not patients have factor VIII inhibitors, according...
Conference Coverage
Gene therapy reduces ABR, AIR in hemophilia B
GLASGOW—New research suggests the gene therapy SPK-9001 can reduce bleeding and the need for factor IX infusions in patients with hemophilia B....
Conference Coverage
N9-GP has better PK profile than rFIXFc, team says
GLASGOW—Nonacog beta pegol (N9-GP) has a better pharmacokinetic (PK) profile than recombinant factor IX-Fc fusion protein (rFIXFc), according to...
Conference Coverage
Therapy can extend half-life of FVIII
GLASGOW—Preliminary data suggest an investigational therapy can extend the half-life of factor VIII (FVIII) in patients with severe hemophilia A...
Conference Coverage
Emicizumab reduces bleeding in hemophilia A
GLASGOW—Final results from the HAVEN 3 study suggest emicizumab prophylaxis can reduce bleeding in hemophilia A patients without factor VIII...
News
FDA approves drug for thrombocytopenia in CLD
The US Food and Drug Administration (FDA) has approved avatrombopag (DOPTELET®), a second-generation thrombopoietin receptor agonist....
Conference Coverage
Design limitations may have compromised DVT intervention trial
WASHINGTON – The preferred evaluation – intravascular ultrasound – was not used.
News
Rivaroxaban vs dalteparin for VTE in cancer
Rivaroxaban is a feasible alternative to low-molecular-weight heparin (LMWH) for the treatment of venous thromboembolism (VTE) in cancer patients...
News
How ruxolitinib reduces thrombosis in MPNs
Preclinical research helps explain how the JAK1/2 inhibitor ruxolitinib can reduce thrombosis in patients with myeloproliferative neoplasms (MPNs...